European expansion The company is actively expanding its European footprint with a dedicated R&D subsidiary in Liège, Belgium, established in August 2025, and has added independent board members to strengthen governance. This suggests opportunities for regional partnerships, clinical development collaborations, and grant or funding alignments within Europe.

Fundraising momentum Recent venture funding of 11.8 million USD in February 2026 indicates strong investor confidence and potential for co-investment, strategic alliances, or joint programs with pharma companies seeking early access to innovative oncology platforms.

Lead program focus Lead candidate TAX2 targets the TSP-1/CD47 pathway and has progressed to Phase 1/2a in advanced solid tumors after European CTA approval, signaling a near-term opportunity to co-develop or license complementary modalities, biomarkers, or combination strategies in solid tumors.

Clinical & tech edge The company emphasizes an in silico discovery platform alongside a peptide portfolio, presenting a chance to offer computational biology collaboration, data-sharing agreements, and technology licensing for accelerated candidate identification and preclinical validation.

Strategic partnerships Past licensing with SATT Nord and ongoing collaborations imply a pattern of partnering for portfolio expansion; sales opportunities exist in out-licensing, co-development deals, or structured collaborations with mid to large biotech and specialty pharma players looking to enter oncology microenvironment space.